Sputnik V: Kerala in talks with Russia to start manufacturing unit

The Kerala Government is in talks with the Russian authorities to set up its manufacturing unit for the COVID-19 vaccine Sputnik V (aka Gam-COVID-Vac) which was developed by the Gamaleya Research Institute of Epidemiology and Microbiology, Russia.

Russian Direct Investment Fund (RDIF) supports the development of Russia’s COVID-19 vaccine by the Gamaleya Center and is investing in mass production of the vaccine by RDIF portfolio companies. RDIF has already partnered with Serum Institute of India which also manufacture the Covishield vaccine for the mass production of over 300 million doses of Sputnik V jabs in India planning to commence production in September 2021.

Dr Reddy’s Labs has also been in partnership with RFID for marketing and distribution of over 250 million doses of Sputnik V. 

RDIF has shown interest in the proposal submitted earlier by the Kerala Government through Russian Ambassador to India Nikolay Kudashev. As per the latest reports, two options are given; the first one is a short term immediate project in which bulk vaccine is imported directly from Russia and the vials can be filled up here. If materialized, Kerala State Drugs & Pharmaceuticals Ltd (KSDPL) will be heading this project after finalizing the modifications which are being worked on the land allotment. 

The long term second option is regarding the setting up of the Sputnik V vaccine manufacturing plant, a Green Field project likely to be at Bio 360 Life Sciences Park. Bio360, Kerala’s first Life Sciences Park and a Kerala State Industrial Development Corporation (KSIDC) initiative, is aiming to be a cluster of research institutions, sci-tech academia and companies, working in the field of Biotechnology, Nano-technology and Life sciences.

KSIDC Chairman & Industries Principal Secretary, Govt of Kerala, Dr K Ellangovan said further talks are being held regarding the finalization of the manufacturing unit.

Author: Alex Dennis

Show More

Related Articles

Leave a Reply

Back to top button